Amarin Corporation (AMRN) CMD 2024 summary

Strategic and operational changes

• Leadership overhaul and new board installed in the past 18 months, with a shift to maximize U.S. cash generation and a new focus on managed care and rebates over sales and marketing.

• Six new regional partnerships executed, and a new commercial and pricing strategy implemented in Europe, leading to successful launches in Spain, U.K., Scotland, and the Netherlands.

• European IP exclusivity extended to 2039, providing a long runway for growth and protection from generic competition.

• Operating expenses reduced by $100 million in 2023 and an additional $50 million in 2024, with a $50 million share repurchase program approved.

• New, leaner operating model in Europe prioritizes country-specific execution, resource optimization, and rapid adaptation to market feedback.

Commercial progress and market expansion

• VASCEPA/VAZKEPA now approved in 46 countries, with early-stage launches and reimbursement in many, and a focus on accelerating growth in Europe and globally.

• Recent pricing and reimbursement wins in Portugal, Greece, Israel, and progress in Italy; Spain and U.K. are driving early European growth.

• Partnerships in China, Australia, and Asia-Pacific are advancing regulatory approvals and commercial launches, with Eddingpharm launching in China and CSL in Australia.

• Over 200 educational initiatives and strong presence at major congresses support brand adoption.

• U.S. market share leadership maintained despite generics, with a strategy focused on managed care access and potential for an authorized generic launch.

Scientific foundation and product differentiation

• REDUCE-IT trial and other studies demonstrate a robust 25% relative risk reduction in major adverse cardiovascular events, with even greater benefit in recent ACS patients.

• Endorsed by over 50 global medical societies, VASCEPA is positioned as a complementary therapy to standard of care, not requiring displacement of other CVOT therapies.

• More than 500 scientific publications and ongoing research reinforce the product's efficacy and safety.

• VASCEPA is unique in addressing residual cardiovascular risk on top of statin therapy, with a strong safety and tolerability profile.